ImmunityBio, Inc. (NASDAQ:IBRX – Get Free Report) dropped 4.5% on Wednesday . The company traded as low as $3.35 and last traded at $3.36. Approximately 546,238 shares traded hands during mid-day trading, a decline of 88% from the average daily volume of 4,516,372 shares. The stock had previously closed at $3.52.
Analyst Upgrades and Downgrades
Separately, Piper Sandler reduced their price objective on ImmunityBio from $6.00 to $4.75 and set a “neutral” rating on the stock in a report on Monday, August 19th.
Get Our Latest Stock Analysis on IBRX
ImmunityBio Stock Down 4.3 %
ImmunityBio (NASDAQ:IBRX – Get Free Report) last released its earnings results on Monday, August 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.03). The company had revenue of $1.05 million during the quarter, compared to analyst estimates of $2.53 million. Sell-side analysts predict that ImmunityBio, Inc. will post -0.86 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in IBRX. Bleakley Financial Group LLC bought a new stake in shares of ImmunityBio during the 1st quarter worth $58,000. Lazard Asset Management LLC lifted its stake in ImmunityBio by 102.6% in the 1st quarter. Lazard Asset Management LLC now owns 13,019 shares of the company’s stock valued at $68,000 after purchasing an additional 6,593 shares during the last quarter. Axxcess Wealth Management LLC acquired a new stake in shares of ImmunityBio during the 1st quarter valued at $85,000. Algert Global LLC bought a new stake in ImmunityBio during the 2nd quarter worth $86,000. Finally, Brookstone Capital Management bought a new position in ImmunityBio in the first quarter valued at about $100,000. 8.58% of the stock is currently owned by institutional investors and hedge funds.
About ImmunityBio
ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.
Featured Articles
- Five stocks we like better than ImmunityBio
- 10 Best Airline Stocks to Buy
- 3 Momentum Trades for October With Ample Upside Ahead
- How to Plot Fibonacci Price Inflection Levels
- Roblox Dips on Short Report—Here’s Why It Could Bounce Back Fast
- What is a Death Cross in Stocks?
- 2 Reasons to Jump on Apple Stock Now and 1 Reason to Think Twice
Receive News & Ratings for ImmunityBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunityBio and related companies with MarketBeat.com's FREE daily email newsletter.